# Tudor–Eliade Ciuleanu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/tudor-eliade-ciuleanu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 40,795 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 71 |
| i10-index | 169 |
| Last Known Institution | Institute of Oncology Prof. Dr. Ion Chiricuta |
| OpenAlex ID | https://openalex.org/A5001591653 |
| ORCID iD | https://orcid.org/0000-0003-0958-5597 |
| Works | 311 |

## Researcher papers

- [Erlotinib in Previously Treated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/erlotinib-in-previously-treated-non-small-cell-lung-cancer/)
- [Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden](https://scholariq.org/papers/nivolumab-plus-ipilimumab-in-lung-cancer-with-a-high-tumor-mutational-burden/)
- [First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer](https://scholariq.org/papers/first-line-nivolumab-in-stage-iv-or-recurrent-non-small-cell-lung-cancer/)
- [Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-docetaxel-versus-placebo-plus-docetaxel-for-second-line/)
- [Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study](https://scholariq.org/papers/ramucirumab-versus-placebo-in-combination-with-second-line-folfiri-in-patients/)
- [Perioperative Nivolumab in Resectable Lung Cancer](https://scholariq.org/papers/perioperative-nivolumab-in-resectable-lung-cancer/)
- [Overall Survival Improvement in Patients with Lung Cancer and Bone Metastases Treated with Denosumab Versus Zoledronic Acid: Subgroup Analysis from a Randomized Phase 3 Study](https://scholariq.org/papers/overall-survival-improvement-in-patients-with-lung-cancer-and-bone-metastases/)
- [First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial](https://scholariq.org/papers/first-line-nivolumab-plus-ipilimumab-in-advanced-nsclc-4-year-outcomes-from-the/)
- [Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial](https://scholariq.org/papers/telisotuzumab-vedotin-monotherapy-in-patients-with-previously-treated-c-met/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [Institute of Oncology Prof. Dr. Ion Chiricuta](https://scholariq.org/institutions/institute-of-oncology-prof-dr-ion-chiricuta/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.